Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amneal Pharmaceuticals ( (AMRX) ) just unveiled an announcement.
On April 21, 2026, Amneal agreed to acquire 100% of Kashiv BioSciences for $375 million in cash, $375 million in stock and up to $350 million in milestone payments, plus royalties, in a deal expected to close in the second half of 2026 pending shareholder and regulatory approvals. The transaction, endorsed by an independent conflicts committee, will create a fully integrated global biosimilars platform aimed at capitalizing on an expected $300 billion-plus biologics loss-of-exclusivity opportunity, with Amneal highlighting $400 million to $500 million in anticipated financial benefits and a path to maintain a modest leverage profile.
The company also reported strong preliminary results for the quarter ended March 31, 2026, with revenue up 4% to $723 million, net income jumping to $78 million and significant margin expansion driven by Specialty growth and a higher-value mix in its Affordable Medicines and AvKARE businesses. On the back of this performance, Amneal raised its standalone full-year 2026 guidance, positioning the Kashiv acquisition as an accelerator of an already strengthening growth trajectory and further diversification into higher-margin biosimilars over the coming decade.
The most recent analyst rating on (AMRX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.
Spark’s Take on AMRX Stock
According to Spark, TipRanks’ AI Analyst, AMRX is a Neutral.
The score is held back mainly by weak valuation (very high P/E) and a still-mixed financial profile marked by historically stressed balance-sheet periods and volatile profitability, despite improving cash generation. Earnings-call guidance is constructive with expected margin/earnings growth and continued deleveraging, but technical signals show cautious near-term momentum.
To see Spark’s full report on AMRX stock, click here.
More about Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc. is a diversified, global biopharmaceutical company focused on expanding access to affordable and innovative medicines, with core businesses in generic “Affordable Medicines,” branded Specialty products and the AvKARE distribution arm. The company is increasingly emphasizing biosimilars as a strategic growth pillar, targeting opportunities from a looming global biologics loss-of-exclusivity wave across major markets.
Average Trading Volume: 2,610,161
Technical Sentiment Signal: Buy
Current Market Cap: $4.23B
Learn more about AMRX stock on TipRanks’ Stock Analysis page.